GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » Selling, General, & Admin. Expense

SCNI (Scinai Immunotherapeutics) Selling, General, & Admin. Expense : $2.53 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Scinai Immunotherapeutics's selling, general, & admin. expense for the three months ended in Dec. 2024 was $0.76 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2024 was $2.53 Mil.


Scinai Immunotherapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for Scinai Immunotherapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Selling, General, & Admin. Expense Chart

Scinai Immunotherapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.02 7.63 5.30 4.51 2.53

Scinai Immunotherapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 0.48 0.52 0.76 0.76

Competitive Comparison of Scinai Immunotherapeutics's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Scinai Immunotherapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinai Immunotherapeutics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Scinai Immunotherapeutics's Selling, General, & Admin. Expense falls into.


;
;

Scinai Immunotherapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scinai Immunotherapeutics  (NAS:SCNI) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Scinai Immunotherapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinai Immunotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
Hadassah Ein Kerem Campus, 2nd Floor, Jerusalem BioPark, Jerusalem, ISR
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
Executives
Samuel J Moed director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain director, other: Chairman WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Chief Financial Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv director STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster director 11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia officer: Chief Scientist 6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman director 21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman director, officer: Chief Executive Officer 269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark officer: Chief Operating Officer 27 HAILANOT, HERZLIYA L3 4631214
George Lowell director 33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green director 354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6